Spondyloarthritis & psoriatic arthritis
Early methotrexate treatment for psoriatic arthritis prevention in psoriasis patients – A retrospective cohort study
Authors' conclusion
Early initiation of methotrexate in patients with moderate to severe psoriasis may reduce the risk of developing PsA.
Study context
- Population
- Psoriasis patients treated at a tertiary center, 2014–2024
- Participants
- 629 patients8498.5 person-years
- Exposure
- Early methotrexate (MTX) vs late MTX vs control
- Outcome
- PsA incidence (events per 100 patient years)
Methodological detailslongitudinal, tertiary centre, time-dependent Cox proportional hazard model, sensitivity analyses
- Longitudinal
- Tertiary centre
- Time-dependent Cox proportional hazard model
- Sensitivity analyses
Main finding
As reported in the abstract
PsA incidence (events/100 patient years)
Adjusted hazard ratio
0.24
P < 0.001
Early MTX vs Control
Adjusted hazard ratio
0.36
P < 0.01
Early MTX vs Late MTX
- Overall psoriatic arthritis (PsA) risk
- 3.51 events per 100 patient years
Observational data: associations, not effects.
Further findings
Sensitivity analyses: biologic-naïve patients and minimum follow-up of 10 years
- Effect persisted in patients naïve to biologics and with a minimum follow-up of 10 years
Original publication
Early methotrexate treatment for psoriatic arthritis prevention in psoriasis patients – A retrospective cohort study. Joint Bone Spine. Published 21 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →